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DNA vaccines expressing the envelope (Env) of the human immunodeficiency virus type 1 (HIV-1) have been relatively ineffective at
generating high-titer, long-lasting, neutralizing antibodies in a variety of animal models. In this study, DNA vaccines were constructed to
express a fusion protein of the soluble human CD4 (sCD4) and the gp120 subunit of the HIV-1 envelope. To enhance the immunogenicity of
the expressed fusion protein, three copies of the murine C3d (mC3d3) were added to the carboxyl terminus of the complex. Monoclonal
antibodies that recognize CD4-induced epitopes on gp120 efficiently bound to sCD4–gp120 or sCD4–gp120–mC3d3. In addition, both
sCD4–gp120 and sCD4–gp120–mC3d3 bound to cells expressing appropriate coreceptors in the absence of cell surface hCD4. Mice (BALB/
c) vaccinated with DNA vaccines expressing either gp120–mC3d3 or sCD4–gp120–mC3d3 elicited antibodies that neutralized homologous
virus infection. However, the use of sCD4–gp120–mC3d3–DNA elicited the highest titers of neutralizing antibodies that persisted after
depletion of anti-hCD4 antibodies. Interestingly, only mice vaccinated with DNA expressing sCD4–gp120–mC3d3 had antibodies that
elicited cross-protective neutralizing antibodies. The fusion of sCD4 to the HIV-1 envelope exposes neutralizing epitopes that elicit broad
protective immunity when the fusion complex is coupled with the molecular adjuvant, C3d.
D 2004 Elsevier Inc. All rights reserved.
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The gp120 subunit of the envelope (Env) protein of the
human immunodeficiency virus type 1 (HIV-1) is respon-
sible for binding to cell surface receptors and the gp41
subunit of Env mediates fusion between the viral and
cellular membranes in a set of defined steps (Ross et al.,
1999; Weissman et al., 1997; Wyatt and Sodroski, 1998).
Binding of gp120 to its primary receptor, human CD4
(hCD4), results in a conformational change in gp120
(Dalgleish et al., 1984; Klatzmann et al., 1984; Maddon et0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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1 Contributed equally to this work.al., 1985; Sattentau and Moore, 1991; Sattentau et al.,
1993). This structural change enables gp120 to interact with
a coreceptor, generally human CCR5 or CXCR4 (Lapham et
al., 1996; Trkola et al., 1996; Wu et al., 1996), that results in
a second conformation in Env, which leads to infection of
the target cell.
The binding of soluble hCD4 (sCD4) to Env, similarly to
membrane-associated hCD4, induces conformational
changes in gp120 (Doranz et al., 1999; Salzwedel et al.,
2000; Sattentau and Moore, 1991; Sattentau et al., 1993)
and allows gp120 to interact with a coreceptor (Doranz et
al., 1999; Lapham et al., 1996; Trkola et al., 1996; Wu et al.,
1996). Upon Env binding to hCD4, the coreceptor binding
site can be exposed for a prolonged period of time (N30
min), which is lost upon hCD4 dissociation (Doranz et al.,
1999). In addition, the induced conformational change in
gp120 involves specific structural changes and not simply04) 292–300
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(Doranz et al., 1999).
The use of a variety of gp120 immunogens has failed to
induce antibodies capable of neutralizing more than a
fraction of primary isolates (Graham, 2001; Mascola,
2003; Spearman, 2003). However, the elicitation of neu-
tralizing antibodies appears to be a critical component of
any HIV vaccine (Graham, 2002; Letvin, 2002). A more
permanent exposure of the conserved coreceptor-binding
site to elicit neutralizing antibodies directed against this
region requires new vaccine approaches. Previous use of an
HIV envelope intermediate formed by the binding of hCD4
and gp120 demonstrated that cross-linked gp120–CD4
complexes induce anti-Env antibodies that were directed
against the hCD4-induced epitopes on gp120 (DeVico et al.,
1996; Fouts et al., 2000; He et al., 2003). However, the
reversibility of hCD4-induced conformations has implica-
tions for vaccine development. The administration of
gp120–sCD4 complexes for immunization may quickly
dissociate in vivo and therefore, gp120 will quickly revert to
a native structure. The dissociation of the gp120–CD4
complex in vivo may reduce the effectiveness of this
vaccine.
DNA vaccines offer an alternative approach for over-
coming the dissociation of cross-linked gp120–CD4 com-
plexes by expressing these proteins as a single fusion in
vivo. DNA vaccinations induce protective immunity against
a variety of pathogens (Liu et al., 1998; Robinson and
Pertmer, 2000) that effectively induce both humoral and
cellular immune responses. However, one of the drawbacks
to the widespread use of DNA plasmids expressing gp120 is
this vaccine strategy has not elicited high titer anti-Env
antibodies in vivo. To overcome this problem, our labo-
ratory has demonstrated that a component of complement,
C3d, can be used as a molecular adjuvant to enhance the
levels of neutralizing antibodies to HIV-1 when fused toFig. 1. The first schematic represents the soluble human CD4 molecule used as a
the envelope used as a vaccine insert. The third schematic represents the sCD4–gp
sgp120–C3d3 construct used as a vaccine insert. The fifth schematic represents the
4 glycines and a serine {(G4S)2} were fused at the junctures between sCD4 andmonomeric gp120 (gp120–mC3d) (Bower et al., 2004;
Green et al., 2003; Haas et al., 2004; Ross et al., 2001;
Toapanta and Ross, 2004). Rodents inoculated with DNA
vaccines expressing gp120 or gp140 fused to three copies of
murine or human C3d had enhanced anti-Env IgG titers and
accelerated affinity maturation of antibody, as well as higher
levels of neutralizing antibodies compared to non-C3d fused
envelopes (Bower et al., 2004; Green et al., 2003; Haas et
al., 2004; Ross et al., 2001; Toapanta and Ross, 2004). The
conjugation of mC3d3 enhanced the antibody titer despite
the decrease in expressed protein. In the human immune
system, C3d is one of the final degradation products of the
third complement protein, C3. The C3d receptor, CD21 or
CR2, is located on B cells, follicular dendritic cells, and
possibly some epithelial tissues (Lu et al., 1995, 1996).
However, C3d appears to enhance immune responses by
both CR2-dependent and CR2-independent mechanisms
(Haas et al., 2004). The goal of this study was to use C3d
to enhance the neutralizing antibodies elicited by sCD4–
gp120 fusion proteins expressed from a DNA plasmid.Results
Construction and in vitro expression
DNA plasmids expressing fusion proteins consisting of
sCD4 and the HIV-1 envelope surface gp120 subunit were
constructed. The sCD4 gene expressing the four immuno-
globulin-like domains (Maddon et al., 1985) was fused to
the N-terminus of gp120 (isolates, ADA and IIIB) at the first
constant (C1) domain and three copies of the murine C3d
(mC3d3) (Bower et al., 2004; Dempsey et al., 1996; Green
et al., 2001, 2003; Mitchell et al., 2003; Ross et al., 2000,
2001; Toapanta and Ross, 2004) were added to the carboxyl
terminus (Fig. 1). Proteins of the expected sizes werevaccine insert. The second schematic represents the secreted gp120 form of
120 construct used as a vaccine insert. The fourth schematic represents the
C3d3 construct used as a vaccine insert. Linkers composed of two repeats of
gp120, as well as gp120 and C3d and between each C3d repeat.
Table 1
Expression of DNA vaccine plasmids
Immunogen Supernatant Cell lysate
Vector 10a F 2b 0 F 0
gp120ADA 750 F 125 150 F 30
gp120ADA–mC3d3 325 F 65 110 F 25
sCD4–gp120ADA 470 F 50 250 F 100
sCD4–gp120ADA–mC3d3 230 F 75 85 F 35
gp120IIIB 1150 F 125 675 F 225
gp120IIIB–mC3d3 450 F 75 205 F 90
sCD4–gp120IIIB 715 F 200 375 F 15
sCD4–gp120IIIB–mC3d3 275 F 30 140 F 25
a ng/ml.
b Standard error of the mean (SEM).
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An expected broad band of 115–120 kDa corresponding to
gp120 in both the cell lysate fraction and the supernatant of
transiently transfected cells was detected (Fig. 2). A higher
molecular weight band was observed for gp120–mC3d3
fusion proteins. In addition, the fusion of sCD4 to each
protein did not inhibit the detection of these proteins (Fig.
2). As observed previously (Bower et al., 2004; Green et al.,
2003; Ross et al., 2001), the vast majority of the Env
proteins were secreted into the supernatant (Fig. 2 and Table
1). The addition of mC3d3 to gp120 or sCD4–gp120
decreased the expression of these proteins 50% compared
to non-C3d fused proteins (Fig. 2 and Table 1). However,
sCD4-conjugated gp120s were secreted into the super-
natants with similar efficiency as non-sCD4 versions.
Lastly, there was no evidence of proteolytic cleavage of
the sCD4–gp120–mC3d3 fusion protein.
The addition of sCD4 exposed epitopes on gp120 that
were more easily recognized by the monoclonal antibodies,
17b and 48d, which bind hCD4-induced epitopes on
envelope (Sullivan et al., 1998; Thali, 1993; Wyatt and
Sodroski, 1998). Monoclonal antibodies which recognize
constitutive epitopes on the gp120 surface protein (IgG1b12,
2G12, and F105) efficiently detected each gp120 or sCD4–
gp120 molecule with or without conjugation to mC3d3
(Table 2). The monoclonal antibody, 2F5, which maps to a
linear sequence in gp41, did not recognize any of the fusion
proteins. Interestingly, both 17b and 48d monoclonal
antibodies bound sCD4–gp120 fusion proteins at a higher
dilution of antibody than gp120 only or gp120–mC3d3,
regardless of the strain of envelope (Table 2). Therefore,
expression from a DNA plasmid of the fusion of sCD4 to
gp120 exposes cryptic epitopes on the gp120 molecule.
Binding of gp120 to cell surface receptors
sCD4–gp120 with or without mC3d3 conjugation were
radiolabeled to determine if the fusion proteins could bind
cell surface HIV-1 coreceptors. gp120 proteins interactedFig. 2. Expression of vaccine constructs in vitro probed with human patient
antisera (HIV-Ig). Human embryonic kidney cells, 293T, were transfected
with 2 Ag of each vaccine plasmid. Supernatant was collected and 1.5% of
total volume was electrophoresis on a 10% polyacrylamide gel. Lane 1 and
5: gp120ADA–DNA, Lane 2 and 6: sCD4–gp120ADA–DNA, Lane 3 and 7:
sCD4–gp120ADA–DNA, Lane 4 and 8: sCD4–gp120ADA–mC3d3–DNA.
Panel A: supernatants and Panel B: cell lysate.with membrane-bound hCD4 expressed on the surface of
transiently transfected cells (Table 3), however, binding to
cell surface coreceptors (hCCR5 or hCXCR4) was strictly
dependent on the presence of sCD4. sCD4–gp120ADA
directly bound to cells expressing hCCR5, but not cells
expressing hCXCR4 and sCD4–gp120IIIB bound to cells
expressing hCXCR4, but not cells expressing hCCR5 (Table
3). The addition of mC3d3 to the 3V end of the fusion
protein did not affect the binding of sCD4–gp120 to the cell
surface coreceptors. To demonstrate the specificity of this
assay, the addition of non-radioactive proteins (data not
shown) or anti-coreceptor (anti-hCCR5 or anti-hCXCR4)
antibodies efficiently competed with sCD4–gp120 binding
(Table 3). These results demonstrate that the sCD4–gp120
proteins, alone or conjugated mC3d3, were able to expose
the cryptic chemokine receptor binding sites on gp120,
which allowed binding to specific chemokine receptors.
Antibody response to gp120–mC3d DNA immunizations
As previously reported (Bower et al., 2004; Green et
al., 2003; Haas et al., 2004; Ross et al., 2001; Toapanta
and Ross, 2004), mice vaccinated with DNA plasmids
expressing gp120–mC3d3 raised higher titers of anti-Env
antibody (IgG) than gp120–DNA (Fig. 3). In addition, the
titers of anti-Env antibody were boosted following
subsequent inoculations with gp120–mC3d3–DNA (weeks
12 and 18) (Figs. 3A and B). In comparison, mice
vaccinated with sCD4–gp120–mC3d3–DNA had an aver-
age peak titer that was approximately 1 log lower than
mice vaccinated with gp120–mC3d3–DNA (week 20).
Interestingly, even though the anti-Env titers in sCD4–
gp120–mC3d3–DNA-vaccinated mice were boosted with
the second inoculation, these titers did not appear to
increase with subsequent inoculations.
Mice vaccinated with any of the sCD4–gp120–DNA or
sCD4–gp120–mC3d3–DNA plasmids had anti-CD4 anti-
bodies (Fig. 4A). Anti-CD4 antibodies (approximately
1:10000) were detected after the initial inoculation and
were boosted after each subsequent vaccination. Interest-
ingly, the anti-CD4 titers elicited by sCD4–gp120–mC3d3–
DNAwere approximately 1 log lower (1:103) than the titers
Table 2
Binding titer of monoclonal antibodies to expressed proteins
Monoclonal antibody sCD4 gp120IIIB gp120IIIB–mC3d3 sCD4–gp120IIIB sCD4–gp120IIIB–mC3d3
F105 b1:10 1:50000a 1:25000 1:25000 1:25000
IgG 1b12 b1:10 1:50000 1:25000 1:50000 1:50000
2G12 b1:10 1:1000 1:1000 1:1000 1:1000
2F5 b1:10 b1:10 b1:10 b1:10 b1:10
48d b1:10 1:1000 1:1000 1:25000 1:25000
17b b1:10 1:1000 1:1000 1:25000 1:25000
a Endpoint dilution titers.
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addition, no anti-C3d antibodies were detected in mice
vaccinated with C3d-conjugated antigens (data not shown).
Sera was subjected to multiple rounds of CD4 depletion
and then re-examined for anti-CD4 antibodies. The addition
of sCD4 to anti-CD4 antisera depleted the serum of CD4
specific antibodies (Fig. 4B), but not Env specific antibodies
(Figs. 4C and D). The titer of anti-CD4 antibodies in sera
from mice vaccinated with sCD4–DNAwere still detectable,
albeit at significantly lower titers (N1:200). However,
following depletion, sera from mice vaccinated with plas-
mids expressing sCD4–gp120 conjugated protein (FmC3d3)
detected hCD4 at a dilution below 1:100 (Fig. 4B).
CD4 conjugated to gp120 enhances titers of neutralizing
antibodies
As observed in our previous studies (Green et al., 2003;
Ross et al., 2001; Toapanta and Ross, 2004), sera from mice
vaccinated with sgp120IIIB–DNA were unable to neutralize
HIV-1IIIB infection (week 20), however, the addition of C3d
enhanced neutralizing antibody titers (1:83 dilution) (Table
4). Not surprisingly, sera from mice vaccinated with sCD4–
gp120IIIB–DNA had no neutralizing antibodies. In contrast,
mice vaccinated with sCD4–gp120IIIB–mC3d3–DNA had
higher titers of neutralizing antibodies (1:225 dilution) than
gp120IIIB–mC3d3–DNA-vaccinated mice (Table 4). Follow-
ing depletion of sCD4 antibodies, all sera had a drop in
neutralizing titers, however, serum from both gp120IIIB–
mC3d3 and sCD4–gp120IIIB–mC3d3-vaccinated mice still
retained the ability to neutralize homologous (HIV-1IIIB), as
well as heterologous (HIV-1ADA) virus infection (Table 4).
Antisera collected from mice vaccinated with plasmids
expressing gp120ADA or sCD4–gp120ADA did not neutralize
virus (N1:10). However, both C3d-conjugated versions ofTable 3
Binding of recombinant proteins to cell surface receptors
Immunogen ADA
hCXCR4 hCCR5 hCCR5 + anti-h
sCD4 115 F 23a 75 F 29 19 F 17
gp120 85 F 14 64 F 31 71 F 40
gp120–mC3d3 153 F 36 40 F 24 21 F 5
sCD4–gp120 43 F 13 16101 F 4766 11 F 7
sCD4–gp120–mC3d3 15 F 12 27010 F 1344 50 F 12
a Counts per minute F SEM.these vaccines did neutralize virus at dilution similar to their
gp120IIIB counterparts against both homologous and hetero-
logous virus infection (Table 4). Once again, the depletion
of anti-CD4 antibodies dropped the overall neutralizing titer,
however, the sera still neutralized viral infection. Therefore,
DNA vaccines expressing a fusion of sCD4 and gp120
elicited detectable levels of neutralizing antibodies only
when conjugated to mC3d3.Discussion
Despite the long time for the appearance of neutralizing
antibody in infected patients (Cole et al., 1997) (6 to 8
months to achieve affinity maturation), this component of
the immune response appears important in controlling
infection. Immunogens that elicit high titer anti-envelope
antibodies are one component of a vaccine needed for a
multi-faceted immune response against HIV-1. The present
study focused on improving the induction of high titer
anti-envelope neutralizing antibodies by expressing a
fusion protein of soluble human CD4 with the gp120
subunit of envelope from a DNA vaccine. The soluble
CD4 molecule conjugated to the HIV-1 envelope has
shown promise as an immunogen for eliciting neutralizing
antibodies directed against cryptic epitopes, only exposed
after binding to cell surface human CD4 (DeVico et al.,
1996; Fouts et al., 2000, 2003; He et al., 2003). One
proposed model indicates that free gp120 can assume a
variety of conformations (Raja et al., 2003); however,
upon CD4 binding, gp120 is locked into a open
conformation that is designed for chemokine receptor
binding. Antibodies that bind the CD4 binding site on
free gp120 prefer to bind other conformations of gp120
and prevent gp120 from assuming the CD4-boundIIIB
CCR5 hCXCR4 hCCR5 hCXCR4 + anti-hCXCR4
85 F 19 20 F 03 12 F 7
38 F 8 98 F 16 54 F 40
99 F 59 100 F 64 47 F 7
20975 F 3197 91 F 66 50 F 45
17560 F 1976 80 F 70 33 F 16
Fig. 3. Anti-Env IgG raised by DNAs expressing sCD4–gp120 proteins in gene gun-vaccinated mice. Mice were primed with DNA at day 0 and boosted at
weeks 6, 12, and 18. Sera were obtained from mice at weeks 0, 6, 8, 12, 14, 18, and 20. () pTR600 vector, (closed square) sgp120–DNA, (open square)
sgp120–mC3d3–DNA, (closed circle) sCD4–gp120–DNA, (open circle) sgp120–mC3d3–DNA. Panel A: constructs using the HIV-1ADA gp120 gene. Panel B:
constructs using the HIV-1IIIB gp120 gene. Sera collected at the indicated times from each mouse was assayed for specific IgG levels by ELISA. Ninety-
six-well plates were coated with recombinant gp120 protein derived Chinese hamster ovary (CHO) cells expressing the HIV-1IIIB. Data are represented as
the average of ten mice. Preimmune sera from mice had no detectable specific IgG. Endpoint dilution titers were conducted by diluting the sera until O.D.
values reached background. Inset: endpoint dilution titer anti-hCD4 antibodies elicited in vaccinated mice.
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locked gp120 molecules are ideal candidates for vaccine
immunogens.
In this study, DNA plasmids were constructed to express
the HIV-1 Envgp120 fused to soluble hCD4 for genetic
immunization. The genes encoding for gp120 were cloned
from two isolates of HIV-1, ADA (R5-tropic) and IIIB (X4-
tropic). Each gp120 gene was cloned in frame with the
carboxyl terminus of a gene segment encoding for the four
extracellular domains of hCD4 (Fig. 1). This sCD4 induced
the exposure of epitopes on gp120 that were recognized by
specific monoclonal antibodies (Table 2). In addition,
sCD4–gp120 molecules efficiently bound to cells express-
ing specific coreceptors indicating that the coreceptor-
binding site was exposed in the fusion molecule (Table 3).
A second set of plasmids was also constructed that
expressed gp120 or sCD4–gp120 fused to mC3d3 (Fig. 1).
To improve the efficacy of DNA vaccines expressing HIV-1
envelopes, our laboratory has previously demonstrated that
the use the C3d component of the innate immune system
enhances the overall titer, the affinity maturation, and the
virus neutralizing ability of the elicited antibody (Bower et
al., 2004; Green et al., 2003; Ross et al., 2001; Toapanta and
Ross, 2004). The addition of mC3d3 to gp120 or sCD4–
gp120 did not inhibit coreceptor binding (Table 3) or the
binding of monoclonal antibodies that recognize CD4-
induced epitopes (Table 2).
Mice vaccinated with DNA plasmids expressing gp120–
mC3d3 or sCD4–gp120–mC3d3 elicited significantly higher
anti-Env antibodies than non-C3d versions (Fig. 3).
Interestingly, mice vaccinated with sCD4–gp120–mC3d3–
DNA had anti-Env antibodies after the second inoculation;however, additional inoculations did not raise the titer of
anti-Env antibodies (Fig. 3). In contrast, mice vaccinated
with gp120–mC3d3–DNA had increasing anti-Env titers
after each vaccination. Most likely the induction of anti-
human CD4 antibodies (Fig. 4) elicited in the vaccinated
mice, inhibited the effectiveness of the sCD4–gp120–C3d3–
DNA booster inoculations (weeks 14 and 20). Mice
vaccinated with sCD4–gp120–C3d3–DNA, as well as
sCD4–gp120–DNA elicited both anti-Env and anti-hCD4
antibodies (Fig. 4). A similar plateau of anti-Env antibody
titers were observed in mice vaccinated with sCD4–gp120
protein complexes (DeVico et al., 1996). Interestingly, even
though no anti-gp120 antibodies were elicited in mice
vaccinated with sCD4–gp120–DNA, the highly immuno-
genic sCD4 portion of the fusion elicited anti-hCD4 titers;
however, these titers were not as high as titers elicited in
mice vaccinated with sCD4–gp120–mC3d3–DNA (Fig. 4).
The anti-CD4 antibody titers were most likely enhanced in
the sCD4–gp120–mC3d3–DNA due to the adjuvant effects
of C3d. In addition, after depleting the sera of anti-hCD4
antibodies, sera from mice vaccinated with sCD4–gp120–
mC3d3–DNA still had high anti-Env antibodies (Fig. 4D).
Antisera from vaccinated mice were also analyzed for the
ability to neutralize virus infection in an in vitro infection
assay (Table 4). Mice vaccinated with gp120–DNA or
sCD4–gp120–DNA did not elicit anti-Env antibodies and
therefore the collected sera did not inhibit viral infection. As
previously reported (Bower et al., 2004; Green et al., 2003),
sera from mice vaccinated with gp120–mC3d3 elicited
neutralizing antibodies that prevented not only homologous
infection, but also heterologous viral infection (Table 4).
Interestingly, even though sCD4–gp120–mC3d3–DNA eli-
Fig. 4. Depletion of anti-hCD4 antibodies from antisera from vaccinated mice. IgG (week 10) endpoint dilution titers from mice vaccinated by DNA vaccines.
Panel A: anti-hCD4 titers. Panel C: anti-Env titers. To deplete anti-human CD4 antibodies from serum, samples were incubated (3) in the presence of bound
CD4 (1 Ag/Al). Samples re-examined for elicited antibodies. Panel C: anti-hCD4 titers. Panel D: anti-Env titers.
J.F. Bower et al. / Virology 328 (2004) 292–300 297cited lower titers of anti-Env antibodies compared to
gp120–mC3d3–DNA-vaccinated mice (Fig. 3), the sera
had a higher neutralizing capacity than sera from mice
vaccinated with gp120–mC3d3–DNA (Table 4).
Both anti-gp120 and anti-hCD4 antibodies most likely
contributed to the neutralizing capacity of the antisera from
vaccinated mice. Previous studies demonstrated that the
neutralizing activity of covalently cross-linked sCD4 and
gp120 molecules resulted in antibodies with two distinct
neutralizing components (DeVico et al., 1996). The first
component included anti-hCD4 antibodies that recognized
epitopes outside the gp120 binding site (DeVico et al.,
1996). The second component was hCD4-independent and
was retained following removal of anti-CD4 antibodies.
Similarly, in this study, sera from mice vaccinated with
DNA plasmids expressing sCD4–gp120–mC3d3 appeared
to have more than one component to neutralizing antibody.
Sera from sCD4–gp120–mC3d3–DNA-vaccinated mice stillretained neutralizing activity after anti-hCD4 antibody
depletion (Table 4).
Surprisingly, even though high titers of anti-hCD4
antibodies were elicited by DNA expressing sCD4 only,
these antibodies did not efficiently neutralize viral infection
(Table 4). In addition, the anti-hCD4 neutralizing compo-
nent of the antisera from sCD4–gp120–mC3d3–DNA-
vaccinated mice was not the major component of the overall
neutralizing capacity of the sera. Depletion of the anti-hCD4
antibodies from sCD4–gp120–mC3d3–DNA-vaccinated
mice dropped the neutralizing activity from 30% to 35%.
There were no detectable anti-mC3d3 antibodies elicited in
the mice and it would be expected that the use of both
human CD4 and human C3d components in this type of
vaccine for vaccination of human patients would not likely
elicit an immune response to these antigens. Therefore, all
the neutralizing capacity of elicited antibodies would be
directed against the gp120 component of this DNA vaccine.
Table 4







sCD4 1:15a 1:10 1:27 1:10
gp120ADA 1:10 1:10 1:10 1:10
gp120ADA–mC3d3 1:80 1:45* 1:38 1:25
sCD4–gp120ADA 1:160 1:100* 1:10 1:10
sCD4–gp120ADA–mC3d3 1:50 1:50 1:85 1:50*
gp120IIIB 1:10 1:10 1:10 1:10
gp120IIIB–mC3d3 1:70 1:70* 1:83 1:70*
sCD4–gp120IIIB 1:10 1:10 1:10 1:10
sCD4–gp120IIIB–mC3d3 1:40 1:40 1:225 1:160**
a Neutralizing titer (50% inhibition).
b Sera depleted of anti-hCD4 antibodies.
* P b 0.05 compared to gp120.
** P b 0.01 compared to gp120.
J.F. Bower et al. / Virology 328 (2004) 292–300298Vaccine strategies that elicit both humoral and cell-
mediated immunity to Env, as well as Gag gene products,
appear to be crucial in limiting viral replication and
protection from live virus infection. The use of immuno-
gens, such as sCD4–gp120–mC3d3, that can elicit neutral-
izing antibodies to a variety of HIV-1 isolates will be an
important component of a protective AIDS vaccine.Material and methods
Construction of sCD4–Env–C3d3
pTR600, a eukaryotic expression vector, has been
described previously (Bower et al., 2004; Green et al.,
2001; Mitchell et al., 2003; Toapanta and Ross, 2004).
Previously, gp120 expression plasmids and gp120–C3d
fusion constructs have been characterized (Green et al.,
2001; Ross et al., 2001; Toapanta and Ross, 2004). Briefly,
vectors expressing sgp120–mC3d3 fusion proteins were
generated by cloning three tandem repeats of the mouse
homologue of C3d in frame with the sgp120 expressing
DNA. The construct design was based upon Dempsey et al.
(1996) using flexible glycines/serine {(G4S)2} linkers
(Green et al., 2003; Ross et al., 2001). The addition of a
sCD4 to the N-terminus of gp120 was constructed by
cloning a PCR-amplified fragment of CD4 encoding the
amino terminal four immunoglobulin-like (Ig-like) domains
(4D, amino acids 1 to 369). The sCD4 protein does not
contain the transmembrane or cytoplasmic domains. The
resulting plasmids express either sCD4–gp120 or sCD4–
gp120–mC3d3.
The plasmids were amplified in Escherichia coli strain-
DH5a, purified using an endotoxin-free, anion-exchange
resin columns (Qiagen, Valencia, CA) and stored at 20 8C
in dH20. Plasmids were verified by appropriate restriction
enzyme digestion and gel electrophoresis. Purity of DNA
preparations was determined by optical density reading at260 and 280 nm and therefore, each DNA vaccine
inoculation contained N50 fg/Ag of endotoxin per DNA
inoculation.
Transfections and expression analysis
293T cells (5  105 cells/transfection) were transfected
with 2 Ag of DNA using 12% lipofectamine (Life
Technologies, Grand Island, NY, USA) as previously
described (Green et al., 2003; Mitchell et al., 2003; Ross
et al., 2001; Toapanta and Ross, 2004). Quantitative antigen
capture ELISAs were conducted on supernatants and cell
lysates as previously described (Green et al., 2003; Mitchell
et al., 2003; Ross et al., 2001; Toapanta and Ross, 2004).
Alternatively, the use of monoclonal antibodies (IgG1b12,
2G12, F105, 2F5, 17b, 48d) (Buchacher et al., 1994; Posner,
1993; Thali, 1993; Thali et al., 1992) were used to detect the
fusion proteins in ELISA. Western hybridization analysis on
collected samples was performed as previously described
(Green et al., 2003; Ross et al., 2001; Toapanta and Ross,
2004).
Iodination and binding of sgp120 to cell surface receptors
The gp120, sCD4–gp120, or sCD4–gp120–mC3d3 were
labeled using Iodobead (Pierce, Rockford, IL, USA)
iodination of 10 Ag of protein for 5 min in a 150-Al volume
of PBS, using 250 ACi of Na125I preincubated for 5 min
with one Iodobead. 125I incorporation rates of greater than
approximately 50% resulted in oxidative destruction of
protein that was no longer capable of binding any receptor.
Radiolabeled proteins were purified from free Na125I by
separation through a 0.3-ml Dowex column prepared in a 1-
ml syringe and pre-equilibrated in a mixture containing 50
mM HEPES (pH 7.4), 5 mM MgCl2, 1 mM CaCl2, 1%
bovine serum albumin (BSA), and 150 mM NaCl. Protein
fractions were eluted in the void volume of the column and
the fractions containing peaks of labeled protein were
combined. The integrity of gp120 after radiolabeling was
verified by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and autoradiography.
Env binding assays were performed by re-suspending
cells in 75 Al of HEPES binding buffer (50 mM HEPES [pH
7.4], 5 mM MgCl2, 1 mM CaCl2, 5% BSA, 0.1% NaN3).
Labeled proteins were added to cells in 25 Al of binding
buffer for a total volume of 100 Al. Cells were incubated at
RT for 1 h. Unbound radioactivity was removed by filtering
cells through 25-mm filters (Whatman, Clifton, NJ, USA)
presoaked in 0.2% polyethyleneimine (Sigma, St. Louis,
MO, USA) and thoroughly washed. Filters were counted in
a gamma counter and represented as counts per minute.
Animals and DNA immunizations
Six- to 8-week-old BALB/c mice (Harlan Sprague–
Dawley, Indianapolis, IN, USA) were vaccinated via intra-
J.F. Bower et al. / Virology 328 (2004) 292–300 299dermally via particle bombardment as previously described
(Green et al., 2003; Haynes et al., 1994; Mitchell et al.,
2003; Pertmer et al., 1995; Ross et al., 2000; Toapanta and
Ross, 2004). Mice were immunized with two gene gun
doses containing 2 Ag of DNA per 0.5 mg of approximately
1-Am gold beads (Bio-Rad, Hercules, CA, USA) at a helium
pressure setting of 400 psi.
Immunological assays
An endpoint ELISA was performed to assess the titers of
anti-Env IgG in immune serum using purified HIV-1
gp120IIIB CHO-expressed protein to coat plates as described
(Green et al., 2003; Ross et al., 2001). Sera from vaccinated
mice were allowed to bind and subsequently detected by anti-
mouse IgG conjugated to horseradish peroxidase. Endpoint
titers were considered positive that were two-fold higher than
background. Similar ELISAs were performed for detection of
anti-human CD4 antibodies elicited by vaccination. To
deplete anti-human CD4 antibodies from serum, samples
were incubated in the presence of bound CD4 to deplete the
antisera of anti-human CD4 antibodies, re-examined for anti-
CD4 antibodies by ELISA and then used in neutralization
assays. All assays were done in triplicate.
Neutralizing antibody assays
Antibody-mediated neutralization of HIV-1IIIB was
measured in an MT-2 cell-killing assay (Montefiori et al.,
1998). Briefly, cell-free virus (50 Al containing 500 TCID50
of virus) was added to multiple dilutions of serum samples
in 100 Al of growth medium in triplicate wells of 96-well
microtiter plates and incubated at 37 8C for 1 h before MT-2
cells were added (5  104 cells in 100 Al added per well).
Cell densities were reduced and the medium was replaced
after 3 days of incubation when necessary. Neutralization
was measured by staining viable cells with Finter’s neutral
red when cytopathic effects in control wells were N70% but
less than 100%. Percentage of protection was determined by
calculating the difference in absorption (A540) between test
wells (cells + virus) and dividing this result by the difference
in absorption between cell control wells (cells only) and
virus control wells (virus only). Neutralizing titers are
expressed as the reciprocal of the plasma dilution required to
protect 50% of cells from virus-induced killing. This 50%
cut-off corresponds to a 90% reduction in viral antigen
synthesis.
Virus neutralization of HIV-1ADA by antisera was
determined as follows (Bower et al., 2004): virus was
mixed with antisera from naive or vaccinated mice (1 h) at
37 8C, the virus-cell mixture was added to GHOST R5 cells
in a total volume of 250 Al, containing 20 Ag/ml polybrene.
The neutralizing capacity of antisera was measured by
comparing the reduction in the number of infected cells per
sample to (1) pre-bleed sera and (2) sera from age-matched
naRve mice. Inhibition of virus was assessed by theadditional reduction in infectivity beyond the background
of naive and pre-bleed antisera. Inhibition was measured by
50% inhibition of virus infection (beyond non-specific
inhibition). Samples were run in duplicate assays on the
same day and averaged and data is presented as the average
per group.
Statistics
For statistical analysis of the difference between gp120
fused to multiple copies of murine C3d and gp120 alone or
fused to one copy of murine C3d, Student’s t test was used.
Differences were considered statistically significant when
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